Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 7/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | TAS2R8 | Q9NYW2 | 8/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8021401 | 0.87 | TAS2R8 (0.46) | IGF1RMGLLARTAS2R8 | |
| SCHEMBL12603131 | 0.85 | AR (0.43) | IGF1RMGLLARTAS2R8PPARG | |
| SCHEMBL8023307 | 0.82 | TAS2R8 (0.47) | IGF1RTAS2R8 | |
| SCHEMBL12873224 | 0.82 | TAS2R8 (0.48) | IGF1RTAS2R8 | |
| SCHEMBL8023309 | 0.81 | TAS2R8 (0.46) | IGF1RTAS2R8PPARGPPARDPPARA | |
| SCHEMBL8019464 | 0.81 | TAS2R8 (0.44) | IGF1RTAS2R8 | |
| SCHEMBL8010593 | 0.81 | TAS2R8 (0.44) | IGF1RARTAS2R8PPARGPPARD | |
| SCHEMBL8001620 | 0.80 | LMNA (0.46) | IGF1RTAS2R8 | |
| SCHEMBL8027028 | 0.80 | HTR2A (0.47) | IGF1RARTAS2R8PPARA | |
| SCHEMBL8006275 | 0.80 | TAS2R8 (0.44) | IGF1RTAS2R8PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759366-B2 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2010-07-20 | — | — | US | disclosed |
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| EP-2061767-A1 | ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE | Sanofi-Aventis (FR) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008017381-A1 | ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE | SANOFI-AVENTIS (FR) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | GPR119, GIPR, LIPC | IGF1R 80/4885MGLL 25/4885AR 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.